Upgrade to SI Premium - Free Trial

Northwest Biotherapeutics (NWBO)

0.17 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/21/25 *Est.)

Latest Headlines

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 17 July 20, 2026 6:02 AM - SEC Filing NWBio updated DCVax-L trial data suggests original survival gains were underestimated July 8, 2026 2:25 PM - StreetInsider Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses July 8, 2026 2:24 PM - PR NewsWire NWBio to present DCVax-L survival data at UK neuro-oncology meeting July 2, 2026 2:19 PM - StreetInsider Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting July 2, 2026 2:18 PM - PR NewsWire Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Mar 31 May 15, 2026 4:39 PM - SEC Filing CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities May 11, 2026 8:30 AM - Globe NewsWire Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform April 30, 2026 12:31 PM - PR NewsWire Full Article List